Mr. Antalich is the former Chief Executive Ofﬁcer of ICC Labs Inc. (TSXV), the ﬁrst publicly traded company in the world to sell cannabis to a federal government. Through strategic foresight, determination, commitment, responsibility, teamwork and passion, he led ICC Labs to its successful sale to Aurora Cannabis (TSX) in November 2018. An entrepreneur with a commercial instinct and vision towards business growth, with expertise in the pharmaceutical industry, operations, manufacturing and product development. A savvy negotiator that manages unique relationship building skills. He led the negotiations of a multimillion transaction with one of the largest participants in the cannabis industry.
Biomind Labs is developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules.
We focus our research in transforming biomedical sciences knowledge into fast-acting/controlled-release psychedelics and tailored drug delivery systems targeting specific therapeutic indications that go beyond mental health conditions.
Our commitment is to provide patients and the psychiatric community with novel pharmaceuticals that provide a comfortable, safe and efficient use, by developing:
A unique portfolio of potent psychedelic molecules aimed at providing patients with access to affordable and modern day neuropsychiatric treatments
The most diversified pipeline of clinical trials targeting multiple diseases to seek fast-track approvals and breakthrough therapy designations for novel pharmaceuticals
Complex products, on-demand products, and customized products, controlling the time and place of drug release for the specific needs of each patient
A personalized medicine and a sustainable production to provide a democratic access to our novel pharmaceuticals regardless the income level of patients
Following strict scientific standards to protect patients and help produce reliable clinical trials results
Across every stage of the molecule
to market lifecycle.
- (USPTO) United States Patent and Trademark Office
- (PCT) Patent Cooperation Treaty
- (EPO) European Patent Office
20 patents applications already submitted
Our academic & corporate credentials
Our highly qualified team of scientists with more than fifteen years of experience on psychedelic research, leaded by the neuroscientist who completed the first randomized, placebo controlled clinical trial to test a psychedelic substance in treatment-resistant depression in 2016, aims to go beyond behavioural studies and work on elucidating the biochemical and neurological mechanisms of psychedelics, targeting new therapeutic indications outside mental conditions. A novel approach that positions Biomind as a game changer accross the pharmaceutical side of the psychedelic industry.
An experienced Board and Management with diverse public company experience, life sciences domain expertise form the Department of Neurology at Harvard Medical School and proven experience working with psychotropic substances in several jurisdictions and negotiating with government authorities and health agencies.
Discover Our Team
Alejandro AntalichChief Executive Officer & Director
Oscar LeónChief Financial Officer & Director
A highly experienced Certified Public Accountant with a solid background in Financial Management, Accounting, Project Finance and Risk Analysis, with experience in Agriculture, Cannabis, Mining and Hydropower Industries. US/Canadian GAAP, IFRS knowledge, SEC and TSX reporting and filing experience. Strong sense of teamwork, quality and ethics. A results-oriented individual who demonstrates his abilities to the benefit of the organization. 3+ decades of experience as Certified Public Accountant. 2+ decades of experience as CFO, Financial Controller, Chief Accountant for several Uruguayan, Canadian and American Companies.
Paola Díaz DellavalleChief Scientific Officer
Ms. Díaz Dellavalle has a Ph.D in chemistry and natural molecules with more than 15 years of experience in research, development, and management in biotechnology projects. She has studies in intellectual property and competitive intelligence analysis, with vast experience in patent strategy and technology transfer, specializing in the fields of chemistry, life sciences, pharmacy and biotechnology. During her career, she has led teams of scientists and managed subcontractors for non-clinical studies and new molecule development programs.
Juan PresaChief Legal Officer
Attorney at law from the Catholic University in Uruguay, specializing in corporate, commercial and international law. Juan has worked with companies from diverse industries such as agriculture, mining, cannabis, FinTech, including listed companies both on the New York Stock Exchange and the Toronto Stock Exchange. Juan developed the business expansion of companies through South America, Asia-Pacific and Africa, and participating in mergers and acquisitions of both public and private companies, public offerings and private placement financings.
Draulio Barros de AraujoScientific and Clinical Advisor
Dráulio Barros de Araújo has a Ph.D. in physics applied to medicine and biology, and a pos-doc in radiology. He has worked as a professor at the University of Sao Paulo and since 2009 he holds a full professor position at the Brain Institute (UFRN), Natal, Brazil. He has been doing research with psychedelics since 2006 and has published over 40 scientific papers on the subject. In 2015 he completed a ﬁrst open label trial with ayahuasca in treatment resistant depression, and in 2018 the ﬁrst and only randomized placebo-controlled trial to test a psychedelic substance (ayahuasca) in treatment-resistance depression.
Marcelo FalchiHead of the Psychiatry Research Unit
Dr. Falchi is a psychiatrist (and so far only) licensed Brazilian physician, since the 1960s, to prescribe and monitor sessions with LSD in healthy volunteers in a scientific study (article published by Cambridge University Press, 2021). He has been studying psychedelics since 2017 with projects about Ayahuasca, LSD and Ketamine.
Patricio EspinozaHead of Intellectual Property
Mr Espinoza is a specialist in Intellectual Property and Innovation Management Systems with more than 20 years of international experience. He managed more than 100 projects in R&D with companies from diverse industries. He is a professor of business strategies, innovation, economy, finances, competitiveness and economic development. Mr. Espinoza has an MBA in Philosophy of Technology.
Martín DanersHead of Quality Assurance and Regulatory Affairs
Mr Daners is a Pharmaceutical Chemist, specialized in Hospital Pharmacy. He has more than 20 years of experience in the pharmaceutical industry, in areas of production, warehousing, research and development. Responsible for the implementation and certification of GxP and ISO standards, with vast experience registering pharmaceutical products under the health regulatory authority.
Lucía MininiScientific Laboratory Manager
Ms Minini has a Ph.D in Chemistry with a degree in Biochemistry. She has been working on drug research and development since 2011. Her expertise resides in active pharmaceutical ingredients discovery, isolation and evaluation of their activity.
Florencia FerraroBiomolecular Research Scientist
Ms Ferraro has a MSc in Chemistry oriented to Medicinal Chemistry with a degree in Biochemistry. She has been working on drug research and development since 2013, specializing in synthesis, characterization, and biological evaluation of active pharmaceutical ingredients, both in vitro and in silico.
Pablo MirandaNanotechnology Technician
PMr Miranda is a Pharmaceutical Chemist, specialized in active compounds encapsulation with several systems such as liposomes, solid lipid nanoparticles and other pharmaceutically suitable bioavailability enhancing vehicles.
Analia CastroNanotechnology Technician
Ms Castro is a Biochemistry, with vast experience in the field of Nanomedicine, mainly synthesis and characterization of nanobiosystems, drug delivery and active targeting functionalization as an innovative approach for the medical and pharmaceutical industry.
Ravi SoodChairman of the Board
Mr. Sood is managing director of Signal 8 Limited based in Toronto, Canada. Founder of and the principal investor in several businesses in emerging markets and currently serves as Chairman of Jade Power Trust (TSXV) and Galane Gold Ltd. (TSXV) and as a director of Eve & Co Incorporated (TSXV). He was the founder and Chief Executive Officer of Navina Asset Management Inc., a global asset management firm headquartered in Toronto, Canada. Mr. Sood led the investment activities of Navina and its predecessor company, Lawrence Asset Management Inc., from its founding in 2001 until he sold the firm in 2010. Mr. Sood was educated at the University of Waterloo (B.Mathematics).
Dr. Ben IlligensDirector
Mr. Illigens is a clinician, clinical scientist, biostatistician, clinical informatician, clinical data scientist and teacher, with over 12 years experience in implementing life sciences, healthcare and digital technologies, innovative programs, products and services in the academic, the biotech, pharmaceutical, CRO and life sciences market in Europe, USA, Latin America and Asia. He was the Instructor in Neurology at the Harvard Medical School, Department of Neurology, in Boston from 2008 to 2018. He also managed the Autonomic Nervous Center of the Department of Neurology. Mr. Illigens created the ﬁrst distance, blended-learning program at the Dresden International University in 2014.
Mr. Buchan began his career on the institutional sales desk at GMP Securities in Toronto followed by GMP Europe in London. Mr. Buchan has served as an executive of Newcastle Gold, Elgin Mining, Touchstone Gold and Andean Precious Metals, and has served as a director of several publicly traded companies. Most recently, Mr. Buchan co-founded Tradewind Markets in partnership with IEX Group and Sprott Inc. Backed by leading companies in the precious metals industry, Tradewind provides institutions with a suite of digital solutions in trading, supply chain management, settlement and custody of precious metals. Mr. Buchan holds a degree in Economics from McGill University.
Sept 27, 2022
Biomind and Queen’s University of Belfast Receive Controlled Substances License to Commence the Production of a Novel Transdermal Drug Delivery System
Sept 21, 2022
Biomind Labs Announces Completion of Dosing in Phase II Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression
Jul 27, 2022
Biomind Labs Appoints Former FDA Director
Dr. Thomas Laughren as Medical Advisor for Clinical Trials
May 26, 2022
Biomind Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08 Candidate for Depression & Anxiety in Alzheimer’s Disease
May 9, 2022
Biomind Labs to Argument Which Psychedelic Medicines Will Lead the Industry Into Its Next Phase of Evolution at The National Gallery in London
April 12, 2022
Biomind Labs to Participate in the PSYCH Symposium at the National Gallery in London
Alejandro Antalich, CEO of Biomind Labs commented: “The PSYCH Symposium will be one of the most...
March 30, 2022
Biomind Labs to Present at Benzinga Psychedelics Capital Conference in the U.S. on April 19th 2022
This is a great opportunity to get a comprehensive understanding of Biomind Labs’ diversified portfolio of...
March 24, 2022
Biomind Labs to Commence Commercial Clinical Trial on Its Proprietary Mescaline Candidate BMND06
After a deep and rigourous evaluation of the potential of this new molecule...
March 17, 2022
Biomind Labs Opens a New Clinical Psychedelic Research Facility
With the opening of our new clinical psychedelic research facility, we continue to distinguish ourselves in the global psychedelic landscape...
March 9, 2022
Biomind Labs Receives Approval for a Second Phase II Clinical Trial for Treatment-resistant Depression
In this second Phase II clinical trial, the Company will test a new approach of psychedelic therapies, a psychiatry...
March 3, 2022
Biomind Labs Announces Positive Results on in vivo Studies for Its Proprietary Drug Candidate BMND07
The completion of the in vivo studies on our BMND07 drug candidate represents a major milestone to continue to progress our proprietary psychedelic ...
February 24, 2022
Biomind Labs Announces DTC Eligibility in the United States
We are pleased to have obtained our DTC eligibility, complementing our recent listing approval on the OTCQB Venture Market announced on February 17, 2022...
February 17, 2022
Biomind Labs Announces Upgrade to the OTCQB® Venture Market in the United States
Trading on the OTCQB is another important milestone for Biomind Labs. It strengthens our strategy of enhancing our visibility...
November 24, 2021
Biomind Announces Design of a Pharmaceutical Form for Psychedelic Drug Delivery Using 3D Printing
We announce the successful design of an oromucosal solid pharmaceutical form obtained by 3D printing...
November 18, 2021
Biomind Completes Development of a Thermosensitive Nasal Gel Pharmaceutical Dosage Form
We announce the completion of the development of a novel thermosensitive nasal gel delivery system ...
November 11, 2021
Biomind to Present at H.C. Wainwright 2nd Annual Psychedelics Conference
We announce that Alejandro Antalich, Chief Executive Officer, and Dr. Draulio Barros de Araujo, Scientific and Clinical Advisor, will present ...
September 28, 2021
Biomind Files International Patent Application on Its DMT Candidates Across 153 Global Jurisdictions
We announce that we have filed an international patent application that brings the potential to obtain patent coverage in 153 countries ...
Commitment to transparency with our patients, the medical community, and our investors. Trust, clarity and innovation are the pillars that accompany us in every step we take.
The next generation of pharma.